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Activation of C3 in human serum by the alternative pathway may be induced 
by a variety of substances including microbial polysaccharides such as zymosan 
(1) and gram-negative bacterial lipopolysaccharides (2), and by certain mamma- 
lian  cells,  such as  rabbit  erythrocytes  (Er)  1 and lymphocytes (3), and some 
human lymphoblastoid cell lines (4). Effective C3 cleavage by the alternative 
pathway requires that the reaction advance to a positive feedback mechanism in 
which C3b (5), the major cleavage fragment of C3, interacts with B and I:) (6, 7) 
to form an amplification C3 convertase (C3b,Bb) (8-10). The activity of C3b,Bb is 
enhanced by the binding of properdin (P) (11-13),  a 223,000-mol  wt T-globulin, 
which retards decay of the otherwise labile convertase (11). Endogenous regula- 
tion of this amplification convertase occurs at three points: intrinsic decay of  the 
C3b,Bb complex by irreversible dissociation of Bb, which becomes inactive Bi (8, 
11); extrinsic decay-dissociation of the convertase, even when stabilized with P, 
by displacement of Bb from C3b with fllH, a 150,000 mol wt E-globulin (14, 15); 
and, after a  removal of protective Bb, inactivation of C3b by C3b inactivator 
(C3bINA),  (16-18),  a  95,000 tool wt E-globulin, to prevent regeneration of the 
convertase at that site (19). 
The presence of active ]3 in whole plasma and serum suggests that amplified 
C3 cleavage by the alternative pathway involves either activation of an addi- 
tional protein or merely circumvention of  the normal regulatory mechanisms by 
the reactants already present. Amplification by deregulation does occur when 
serum lacks a  control protein, such as C3bINA (19, 20); contains the pathobio- 
logic protein, C3 nephritic factor (21), which stabilizes and protects C3b,Bb from 
decay-dissociation by B1H (14); or is incubated with cobra venom factor (22), a 
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functional analog of C3b that is  resistant  to  C3bINA  (23).  The concept of a 
continuously operative,  low grade  fluid phase C3b-generating  system  is sup- 
ported by studies of the interaction of purified proteins in the absence of the 
regulatory proteins, C3bINA and BIH. Thus, native C3 and B interact with I3 
to commence B and C3 cleavage (24), and the efficiency of C3 cleavage is greatly 
augmented by the presence of P  (25).  The introduction of C3bINA and ~IH to 
such reaction mixtures prevents their transition to amplified C3 and B inactiva- 
tion and has made possible the demonstration of a mechanism of activation of 
the alternative pathway by E r. C3b deposited on the surface of E r by the low 
grade  fluid phase  reaction  and  the  P.stabilized  amplification  C3  convertase 
(P,C3b,Bb) formed at that site are relatively protected from the action of the 
regulatory proteins, thereby causing membrane-associated amplification of C3 
cleavage. 
Materials and Methods 
Preparation of Alternative Pathway Factors.  B  (6), C3  (24,  26),  fllH (14),  I5 (11),  P  (27),  and 
C3bINA (27) were purified to homogeneity and quantitated as described. Purified P did not contain 
functionally detectable ~: P did not induce C3 and B cleavage upon addition to normal serum (28) 
and did not remain bound to an erythrecyte antibody complement 4b,3b intermediate (EAC4b,3b) 
during washing in isotonic buffer (29).  300 ~ag purified C3bINA emulsified in complete Freund's 
adjuvant yielded a  monospecific rabbit antiserum that recognized no antigens in human serum 
genetically deficient in C3bINA (19). C3 was trace-labeled with ~zsI  by insolubilized lactoperoxidase 
(30)  (Worthington  Biochemicals Corp.,  Freehold,  N. J.).  To establish  purity,  25-50  /~g of each 
alternative pathway protein was reduced with 0.1 M dithiothreitol in 8 M urea and subjected to 
electrephoresis  in  7%  polyacrylamide gels  containing  0.1%  sodium  dodecyl sulfate  (31),  after 
which the gels were stained  with Coomassie blue.  Each protein preparation  was homogeneous 
by densitometric scanning and  exhibited the appropriate  molecular weight for its polypeptide 
chains. B (32), 13 (32), P (33), and B1H (15) each demonstrated a single stained band corresponding 
to tool wt of 100,000,  25,000,  58,000,  and  150,000,  respectively. In the case of P,  the molecular 
weight represents four apparently identical noncovalently linked subunits  (33). C3  (34,  35) and 
C3bINA (27),  which consists of two nonidentical covalently linked polypeptide chains,  revealed 
two bands which were 125,000 and 80,000 tool wt for C3, and 55,000 and 42,000 tool wt for C3bINA. 
Assays.  Veronal-buffered saline,  pH 7.5,  containing 0.1% gelatin (GVB),  1.5  ×  10 -4 M  cal- 
cium, and 5  x  10 -4 M magnesium (GVB++),  half-isotonic GVB  ++ with 2.5% dextrose (DGVB++), 
and GVB containing 0.04  M  ethylenediamine tetraacetate  (EDTA) (GVB-EDTA) were used as 
diluents (36). Erythrocytes from sheep (E  s) and New Zealand albino rabbits (E  r) were collected into 
Alsever's solution,  washed in saline,  and stored in GVB-EDTA. The quantitative relationship 
between the number of molecules of C3b bound to erythrocytes and the number of hemolytically 
active convertase sites generated upon interaction with P, B, and I3 was examined with E~C3b and 
ErC3b formed with increasing amounts of ~sI-C3. Replicate samples of 4 x  10  s E  ~ and E  r containing 
500 ~g B and 1.0/~g 13 were incubated with 800, 400, 200/~g, or no x25I-C3 in 2.0 ml DGVB  ++ for 60 
min at 30°C. The cells were washed twice with GVB-EDTA, incubated for an additional 120 min at 
37°C  in  GVB-EDTA,  and  washed  in  DGVB ++.  The number  of C3b molecules/erythrocyte was 
calculated from the i~sI bound in the presence of B  and 13 after subtracting  ~25I nonspecifically 
bound in the absence orb and I~. C3b hemolytic activity was assayed by incubating 1 x  107 E~C3b 
and ErC3b with 0.2 pg P, 10 ng I3, and 10 ng B in 0.2 ml DGVB  ++ for 30 min at 30°C. After addition 
of 0.3  ml rat serum diluted 1:20 in GVB-EDTA and further incubation of the cells for 60 rain at 
37°C,  the percent hemolysis was determined and the average number of hemolytic sites/cell (Z) 
was calculated, with reaction mixtures containing the E s and E r previously incubated with B and 
13 alone serving as reagent blanks. Uptake of ~25I-C3b at the three inputs of 1~I-C3 was 0.14, 0.14, 
and 0.13%,  respectively, for E  ~ and 0.22, 0.19, and 0.18%,  respectively, for E% Lysis of EsC3b and 
ErC3b was linearly related to the number of C3b molecules/cell, and EsC3b was 3.5 times more 
susceptible to complement-mediated lysis than ErC3b at equivalent amounts ofbeund C3b (Fig. 1). 
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Fro.  1.  Number of hemolytic sites/cell (Z) formed by interaction of constant amounts of 
P, B, and 13 with E~C3b (@--@) and ErC3b (©--O) bearing increasing numbers of 125I-C3b 
molecules/cell. 
hemolytic activity was developed with 0.2 ttg P, 10 ng 13, and 5 ng B for E~C3b and 0.2 tLg P, 10 ng 
13, and 25 ng B for ErC3b so that hemolysis would be comparable. 
Results 
Resistance of C3b on E r to Inactivation by C3bINA.  The relative susceptibil- 
ity of C3b on EsC3b and  ErC3b to inactivation  by C3bINA was compared by 
incubating  1  ×  107 of each intermediate  in 0.1 ml  GVB  +÷ for 60 min at 37°C 
during which replicate samples received 0.1 ttg C3bINA in 0.1 ml GVB  ++. Each 
reaction was stopped by addition of 2 ml ice-cold GVB  ++,  sedimentation,  and 
washing of the intermediates at 4°C. Loss of C3b activity from EsC3b and ErC3b 
proceeded as first order reactions, but the rates of inactivation differed markedly 
(Fig.  2).  C3b on E~C3b  exhibited a  half-life (t½) of 41  min  in the  presence  of 
C3bINA with 64% loss of activity in 60 min,  while C3b on ErC3b lost only 8% 
activity and had an estimated tt of 480 min.  Since ~IH has been observed to 
augment inactivation of C3b by C3bINA (15), the experiment was repeated with 
0.05  fig C3bINA and 0.5  P4g/31H.  C3b on ErC3b again demonstrated  relative 
resistance to inactivation when compared to E~C3b,  with the former intermedi- 
ate having a  tt of 220 min and the latter  a  t½ of 16 min.  To establish that the 
resistance  of C3b on E~C3b  to the  regulatory proteins  existed under  natural 
circumstances,  the  experiment  was  repeated  with  0.1  ml  of normal  human 
serum  diluted  1:100  with  GVB-EDTA  instead  of purified  C3bINA  and  B1H. 
ErC3b again demonstrated relative resistance to inactivation, with C3b function 
declining  14%  in  60  min,  yielding  a  t½  of 280  min;  while  E~C3b  was  86% 
inactivated in the same interval with a  t½ of 22 min. 
Resistance  of P,C3b,Bb,  on E r to Decay-Dissociation  by  fllH.  The  suscep- 
tibility of the P-stabilized amplification convertase on E ~ and E ~ to ~lH-medi- 
ated decay-dissociation was examined by comparing the dose-response effects 
of B1H on the decay of the cell-bound convertases.  E~C3b  and E~C3b,  4  ×  l0  s, D,  T.  FEARON  AND  K.  F.  AUSTEN  25 
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FIG.  2.  Time-course of inactivation of C3b  bound to  E s  (@---@)  and E r  (O---©)  during 
incubation with C3bINA (lei~ panel), C3bINA and 131H (middle panel) and normal human 
serum diluted in GVB-EDTA (right panel). 
were incubated with 8 ~g P, 0.4 ~g I), and 0.2 ~g B for EsC3b and 8 ~g P, 0.4 
~g ]5, and 1 ~g B for ErC3b in 6 ml DGVB +÷ for 30 min at 30°C to generate the 
intermediates bearing P,C3b,Bb.  Intermediates lacking P  also were formed by 
incubating I  ×  108 ~C3b with 0.1 ~g I5 and 1 ~g B, and 1 ×  108 E~C3b with 0.1 
~g I)  and 5  ~g B.  The intermediates bearing the P-stabilized  amplification 
convertase were washed twice with ice-cold GVB-EDTA diluted 1:1  with 5% 
dextrose, and 1 ×  108 of each intermediate were resuspended at 30°C in 2 ml of 
the same buffer alone or containing 0.22, 0.66, or 2.0 ~g fllH. The intermediates 
formed in  the  absence  of P  were washed  and  resuspended in  buffer alone. 
Incubation was continued at 30°C, and 0.2-ml samples were removed at varying 
intervals  and added to  rat serum diluted 1:20 in  GVB-EDTA to develop the 
residual convertase sites. The t½'s of E~C3b,Bb  and E~C3b,Bb were 4 min, and P 
effected similar degrees of stabilization,  extending the t½'s to 28 and 29 min, 
respectively (Fig. 3). The susceptibility of EsC3b,Bb,P to flirt-mediated decay- 
dissociation was such that 0.22 ~g/31H reduced the t~ to 11 min and 2.0 ~g fllH 
reduced the t½ to less than that of  the unstabilized convertase. In contrast, 2.0 ~g 
131H reduced the t½ of ErC3b,Bb,P only to 12 min. Thus, E r did not change the 
requirement for P-stabilization or alter the intrinsic decay of the amplification 
convertase,  but  did protect the P-stabilized convertase from extrinsic decay- 
dissociation by 131H. 
Interaction of E r with the Alternative Pathway Reconstructed with Purified 26  CIRCUMVENTION  OF  ALTERNATIVE  PATHWAY  CONTROL  PROTEINS 
Z 
t .0 ~ 
0.5 
0. t 
0 
SHEEP  RABBIT 
ESC3b, Bb, P (~-~)  ErC3b, Bb, P (H) 
EsC3b, Bb  (~-"~)  ErC3b, Bb  (o-..o) 
\ 
0  .  .  . 
I  ~J  I  "  -g  ] 
t0  20  :$0  0  t0  20 
MINUTES 
FIG. 3.  Time-course of  decay of  Z on ~C3b, Bb, P (A--A, left  panel),  and ErC3b, Bb, P 
($---O,  right  panel) alone and in  the  presence of  increasing amounts of  ~IH. Decay of  sites 
on E~C3b, Bb (/x--/x)  and ErC3b, Bb (O--©) in buffer  alone is indicated  by dashed lines. 
Proteins.  The alternative complement pathway was reconstructed with 1/loth 
serum levels of purified C3, B, I), P, C3bINA, and ~IH. Two identical reaction 
mixtures containing 70 ~g C3, 12.5 ~g B, 0.05 ~g I5, 1.25 ~g P, 2.5 ~Lg C3bINA, 
and 25 ~g ~IH in 0.5 ml GVB ÷+ were prewarmed to 37°C and added to I  × 10  g 
and E  r, respectively. During further incubation at 37°C, two samples of 25  ~1 
were removed at each timed interval from each reaction mixture. One sample 
was added to 2.5 ml ice-cold DGVB ++ and centrifuged, and the supernate was 
assayed for hemolytically  active C3 and B. The other sample was added to I ml 
rat serum diluted 1:50 in GVB-EDTA and incubated for 60 min at 37°C, after 
which the percent hemolysis of E  s and E  r was measured. In the presence of 
only low grade inactivation of C3 and B occurred, reaching 10% in 60 min. In 
contrast,  E  r  induced about  50%  inactivation of C3  and B  by  10  min which 
reached 76 and 93% inactivation of C3 and B, respectively, at 30 rain (Fig. 4). 
was not converted to an intermediate that could be lysed by the source of C3-C9, 
while lysis of ~  increased from 0 to 40% in the first 20 rain, declining thereafter 
to 8% by 60 min. Thus, E  ~ had no effect on the regulated mixture of alternative 
pathway proteins, while E  r markedly amplified C3 and B inactivation and was 
converted to an intermediate susceptible to lysis by C3-C9. The Tmax kinetics 
observed for the lysis of the E ~ intermediate reflect reexpression of endogenous 
control mechanisms aider fluid phase C3 and B have been largely consumed. 
To  assess  directly the  capacity of the  alternative pathway reaction with 
purified proteins to deposit C3b on the activating target cells, the reaction was 
repeated with  1~I-C3 in  the  presence and  absence of ~IH.  Three reaction 
mixtures, each containing 1~I-C3, B, I), P, C3bINA, and ~IH in 0.5 ml GVB  ÷+ in D.  T.  FEARON  AND  K.  F.  AUSTEN  27 
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FIG.  4.  Interaction of E r and E s with the alternative complement pathway reconstructed 
with purified C3, B, IT), P, C3bINA, and fllH. Lower panel: time-course of inactivation of C3 
(O--@) and B (O--©) by E r and of C3 (A--A) and B  (A--A) by E% Upper panel: kinetics of 
generation of hemolytically active sites on E r (~--O) but not on E ~ (A--A) taken from the 
reaction mixtures depicted in the lower panel at the times indicated. 
the concentrations noted above, and three reaction mixtures of the same pro- 
reins except for/31H were incubated at 37°C alone, with 2 x  109 E s and with 2 × 
109 E  ~, respectively. 100-/~1 samples were removed at timed intervals and added 
to 5 ml ice-cold DGVB++; the cells were sedimented and the supernates removed 
for hemolytic assay of C3. The cells were washed four times in GVB-EDTA and 
assessed for bound 125I-C3b. Control reaction mixtures containing the proteins 
and cells in 0.5 ml GVB-EDTA were treated identically and established that 
nonspecific binding  of ls5I-C3 was less than  0.2%  for both  cell types.  In  the 
presence of fllH, E ~ induced 82% inactivation of C3 in 30 min; this inactivation 
was accompanied by net binding of 125I-C3 that was equivalent to 12.4% of  the C3 
molecules cleaved (Table I). In the absence of fllH, 100% of the C3 was inacti- 
vated within 15 min and net binding of ~25I-C3b was reduced to 0.14% of the C3 
input. Minimal inactivation and negligible binding of ~25I-C3 occurred with E  s in 
the  complete  reaction  mixture.  The  omission  of ~IH  resulted  in  rapid  C3 
inactivation with net ~25I-C3b uptake that was 0.16% of the initial C3 input. C3 
inactivation was also complete by 15 rain in the/31H-deficient reaction mixture 
incubated without erythrocytes, indicating that the absence of this regulatory 
protein permitted amplified cleavage of C3 to occur in the fluid phase.  Thus, 
deregulation of endogenous controls at the surface of E r but not E s results in 28  CIRCUMVENTION  OF  ALTERNATIVE  PATHWAY  CONTROL  PROTEINS 
TABLE  I 
Binding and Inactivation of r~I-C3 by E r and E s during Incubation  with Purified 
Alternative Pathway Proteins 
Time 
Rabbit erythrocytes  Sheep erythrocytes 
with/]IH  without B1H  with BIH  without B1H 
125I.  125  I_  125 I.  ~25 I. 
C3b/E  r  C3 inac-  C3b/E  r  C3 inac-  C3b/E  s  C3 inac-  C3b/E  s  C3 inac- 
(mole-  tivated  (mole-  tivated  (mole-  tivated  (mole-  tivated 
cules)  cules)  cules)  cules) 
min  %  %  %  % 
15  9,980  64  150  100  20  3  170  100 
30  11,120  82  130  100  10  5  140  100 
45  9,200  83  130  100  0  9  90  100 
60  7,840  82  120  100  30  14  90  100 
local deposition of C3b by formation and function of surface-bound amplification 
convertase.  In the  absence of the  regulatory protein,  B1H,  the fluid phase 
reaction spontaneously advances to amplification, consuming C3 and B, so that 
specific deregulation at the surface of E  ~ with concomitant accumulation of C3b 
cannot occur. 
Discussion 
Cleavage of C3 by the alternative complement pathway occurs in at least two 
distinct phases: continuous generation of C3b by low grade interaction of native 
C3, B, I5, and P, and subsequent amplified cleavage of C3 by the interaction of 
C3b, B, I), and P. Transition to C3b-dependent amplification of C3 cleavage is 
normally prevented by C3bINA (19, 20) and B1H (14, 15), which limit formation 
and function of C3b,Bb. That the interaction of B and I) with C3b (5) was much 
more efficient than with C3 was recognized in earlier studies (24, 25), but the 
concept that regulatory proteins restricted the reaction to the initial phase could 
not be validated with isolated proteins until the recent characterization of the 
function of B1H. Lachmann and Halbwachs (37) had suggested that the intense 
C3 and B cleavage observed in serum genetically deficient in (19) or immuno- 
chemically depleted of C3bINA  (20) was due to  initial generation of C3b by 
noncomplement-dependent  proteolytic cleavage of C3 followed by unregulated 
amplification. The subsequent finding (24) that interaction of native C3, B, and 
I) led to slow and then rapid inactivation of C3 and B  in the absence of any 
demonstrable contamination of the starting materials with C3b, and even in the 
presence of C3bINA,  indicated that the alternative pathway proteins them- 
selves  could generate  the  initial  C3b.  The  presence  of P  in  such  reaction 
mixtures increased the efficiency of initial C3 cleavage as evidenced by reduced 
requirements for B and I~ and a shortening of the lag phase before amplified C3 
and B inactivation (25). The introduction of both C3bINA and t~lH into reaction 
mixtures of C3, B, I5, and P limits the reaction to low grade C3 cleavage without 
progression to the amplification phase. This circumstance has permitted demon- 
stration that activators of  the alternative pathway, such as zymosan (27) and E r, D.  T.  FEARON  AND  K.  F.  AUSTEN  29 
provide privileged sites that protect C3b deposited by the low grade fluid phase 
reaction and the P,C3b,Bb  formed at that site from the action of regulatory 
proteins, resulting in membrane-associated amplified C3 cleavage. 
The initial experiments demonstrating that E  r, as compared to ~, afforded 
C3b  a  protected location contrasted the effects of inactivating principles  on 
bound C3b. Generation of E~C3b and ErC3b  by incubation of the cells with 
purified ~I-C3,B, and I5 resulted in slightly more binding of ~I-C3b to ~  than 
to E  r. The number of hemolytic sites/cell was linearly related to the number of 
molecules of l~I-C3b/cell,  permitting the precise measurement  of  cell-bound C3b 
activity (Fig.  1).  When these intermediates were treated with C3bINA alone, 
with a  combination of C3bINA and fllH, or with dilute whole human serum, 
inactivation of C3b bound to E  s at 60 rain was 64, 93, and 86%, respectively (Fig. 
2). In contrast, these same treatments had little effect on C3b bound to E  ~, and 
the inactivation at 60 min ranged from 8 to 19%. Thus, C3b molecules bound to 
E  r relative to those on E  s were protected from the action of C3bINA alone or in 
combination with/31H. 
Furthermore, once the P-stabilized amplification convertase had been formed 
on the bound C3b, the surface of E  ~  manifested an additional point of deregula- 
tion. As shown in Fig. 3, intrinsic decay and the magnitude of P-stabilization of 
C3b,Bb was the same on E  ~  and E  ~. However, 10-fold more fllH was required for 
comparable decay-dissociation of P,C3b,Bb on E  r as on ~. Thus, the E  r mem- 
brane,  by  offering a  protected microenvironment for  C3b, facilitates  rapid 
formation of bound amplification convertase which, in turn, is relatively resist- 
ant to the action of fllH and deposits additional C3b by cleavage of C3, thereby 
shifting the alternative pathway to its amplification phase. 
The hypothesis that  the  protective surface of E  r  was  responsible  for  the 
transition from fluid phase low grade to membrane-associated amplified C3 
cleavage was supported by such an occurrence in a reaction mixture consituted 
only of the purified proteins of the alternative pathway. I5 was utilized in these 
reaction mixtures since it was invariably present in plasma and serum. Par- 
tially purified C3bINA had been reported to be contaminated with initiating 
factor, a  fl-globulin consisting of two covalently linked polypeptide chains of 
85,000 mol wt (38, 39). The C3bINA utilized in these reconstitution experiments 
was purified by a different  procedure (27) and revealed only two disulfide linked 
polypeptide chains of 55,000 and 42,000 mol wt when subjected to polyacrylamide 
gel electrophoresis in the presence of sodium dedecyl sulfate. As shown in Fig. 4, 
incubation of P, C3, B, ]), C3bINA,  and/31H at 10% of their serum concentra- 
tions was associated only with low grade C3 and B inactivation, indicating that 
P,  lacking P,  did not advance the fluid phase reaction to amplification. The 
addition ofE  r to the mixture of  these purified proteins resulted in inactivation of 
B  and  C3  in  association  with  formation of membrane-bound amplification 
convertase on E  ~, as indicated by lysis of the E ~ intermediate upon interaction 
with C3-C9. ~  did not advance the low grade C3  and B inactivation, which 
reached approximately 10% at 60 rain, and was not converted to an intermediate 
susceptible to lysis by subsequent exposure to a source of C3-C9. 
To demonstrate that increased C3b fixation by E  ~  resulted from deposition by 
particle-bound amplification C3 convertase rather than by fluid phase conver- 30  CIRCUMVENTION  OF  ALTERNATIVE  PATHWAY  CONTROL  PROTEINS 
tase,  binding of C3b  was  quantitated during reactions in  the presence and 
absence of ~IH. As shown in Table I, interaction of E r with 125I-C3, B, I:), P, 
C3bINA, and ~IH induced 82% inactivation of C3 in 30 min and was accompa- 
nied by a net binding of 11,120 molecules of 125I-C3b/E  ~, which is equivalent to 
12.4% of the C3 cleaved at that time point. In contrast, when ~IH was omitted 
from the reaction mixture there was complete inactivation of C3 within 15 man 
in  the  unregulated fluid phase  reaction  and  the  net  uptake  was  only  150 
molecules of ~25I-C3bfEr, representing 0.14% of the C3 cleaved. Thus, the pres- 
ence of a regulated fluid phase reaction is essential for efficient fixation of C3b 
on the activating principle. As E ~ did not advance the complete reaction to 
amplification, there was no binding of C3b, and the omission of ~IH again led to 
complete inactivation of C3 that produced less than 0.2% net binding of ~25I-C3b. 
The facilitating role in alternative pathway activation of specific antibody and 
classical complement components noted by others (40-42) probably pertains to 
the phase of initial deposition of C3b.  Once C3b  is bound to the protecting 
surface of the activator, the reaction readily shifts to the amplification phase 
because of the increased rate of C3b generation and efficiency of C3b binding 
induced by the particle-bound C3b-dependent convertase. 
The capacity of a microbial surface, by analogy to zymosan and E  ~, to protect 
and thereby accumulate increasing amounts of C3b by local circumvention of 
the regulatory proteins is compatible with a  unique role for the alternative 
pathway in host defense. The specificity of  the pathway resides in the capacity of 
certain surfaces to induce transition from constant low grade fluid phase C3 
cleavage to localized amplification because of the selective inability of C3bINA 
and ~IH to deal with their substrates when deposited on these surfaces. The 
implication of these surface effects would hold even if initial C3 cleavage and 
binding was facilitated by specific antibody and classical  complement or by 
involvement of additional principles. 
Summary 
Cleavage of C3 by the alternative complement pathway occurs in at least two 
distinct phases: continuous low grade generation of C3b by the interaction of 
native  C3,  B,  ]3,  and  P,  and  subsequent  amplified cleavage  of C3  by  the 
interaction of C3b,  B,  I:), and  P  which forms the  amplification convertase, 
P,C3b,Bb.  Transition to C3b-dependent amplification is necessary to achieve 
substantial C3 cleavage and is normally limited by the combined action of C3b 
inactivator (C3bINA) and filH. An activator of  the alternative pathway, such as 
rabbit erythrocytes (Er), provides sites that protect bound C3b and P,C3b,Bb 
from the action of these regulatory proteins and permits C3b deposited by the 
low grade fluid phase reaction to assemble a  membrane-associated amplifica- 
tion convertase which can deposit additional protected C3b. 
Under conditions in which the control proteins,  C3bINA and ~IH,  almost 
completely inactivated C3b bound to sheep erythrocytes (Es), which does not acti- 
vate the alternative pathway, the function of C3b bound to E r was diminished by 
less than one-fifth. Further, the P-stabilized amplification convertase on E ~ was 
10-fold less sensitive to flirt-mediated decay-dissociation than_the convertase on 
E s. The addition ofE  ~  to a regulated mixture of purified C3, B, D, P, C3bINA, and D.  T.  FEARON  AND  K.  F.  AUSTEN  31 
~IH resulted in amplified inactivation of C3 and B by formation of the amplifi- 
cation convertase on E r as indicated by its lysis with subsequent exposure to 
C3-C9.  In contrast, E s did not advance the low grade fluid phase inactivation of 
C3 and B to amplified inactivation and the cell was not converted to an inter° 
mediate susceptible to lysis by C3-C9.  Since E r and E s did not differ in their ineffi- 
cient fixation of C3b generated during an unregulated fluid phase reaction, the 
activating capacity ofE  r must reside in its protection of  bound C3b and P, C3b,Bb 
from the regulatory proteins rather than in enhanced capacity to bind C3b from 
the fluid phase. When the reaction is limited to low grade fluid phase turnover, 
introduction of E r but not E s results in a 100-fold increase in the deposition of C3b, 
indicating that surface-dependent activation of  the alternative pathway is char° 
acterized by efficient deposition of C3b  on  the  initiating  surface.  Thus,  the 
activating surfaces advance the interaction of the alternative pathway proteins 
to the amplification phase because of the selective inability of the regulatory 
proteins to deal  with  their substrates  when deposited on these surfaces and 
results in a specificity that is not necessarily dependent on adaptive immunity. 
Received for publication 14 February 1977. 
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